Complete surgical resection combined with adjuvant chemotherapy is considered to be the most effective treatment of<unk> . Transcathether arterial embolization (TAE), blocking an artery with the help of a catheter to prevent further bleeding or limit blood supply to the tumor, resulting in suppressed growth, is the most effective treatment for spontaneous rupture of the tumor resulting in intra-abdominal bleeding. Transcatheter arterial chemoembolization (TACE), which is the same as TAE, but also involves the regional injection of chemotherapy drugs, has shown effectiveness at increasing survival, particularly in individuals with few dominant masses rather than several smaller. TACE allows for simultaneously increasing regional (and therefore also tumor) exposure to chemotherapy while reducing systemic exposure, which both allows for an increased dose, as systemic exposure is generally the limiting factor, and also reduced side effects of chemotherapy. TACE and TAE are both generally performed on the hepatic artery.<unk> s are generally reported to be radioresistant and therefore radiation therapy is not considered an effective treatment. Although previously considered a viable treatment option, liver transplantation is no longer considered for<unk> , due to its high reoccurrence rate and poor post transplantation survival. The European Liver Transplant Registry considers<unk>  an absolute contraindication to liver transplantation, reporting that the median survival following liver transplantation is less than 7 months with no one surviving more than 23 months, showing very little difference from no treatment at all.
Liver angiosarcoma
Cholangiosarcoma
Cavernous liver hemangioma
Cholangiocarcinoma
Pancreatoblastoma
Liver abscess
Hepatoblastoma
Periampullary cancer